Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine.

Journal Article (Journal Article)

Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.

Full Text

Duke Authors

Cited Authors

  • Thomas, DM; Fox, S; Lorgelly, PK; Ashley, D; Richardson, G; Lipton, L; Parisot, JP; Lucas, M; McNeil, J; Wright, M; Cancer 2015 Investigators,

Published Date

  • December 2015

Published In

Volume / Issue

  • 20 / 12

Start / End Page

  • 1429 - 1432

PubMed ID

  • 26494144

Electronic International Standard Serial Number (EISSN)

  • 1878-5832

Digital Object Identifier (DOI)

  • 10.1016/j.drudis.2015.10.009


  • eng

Conference Location

  • England